Symbols / DBV
DBV Chart
About
The Advisor invests in futures contracts in an attempt to track its index (“index contracts”). The index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | 75.00% |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | 26.46 | 52W Low | 24.25 |
| Beta | — | Avg Volume | 0.00 | Volume | 1.40K |
| Target Price | — | Recom | — | Prev Close | $25.57 |
| Price | $25.41 | Change | -0.63% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
News
RSS: Latest DBV news- Is It Too Late To Consider DBV Technologies (ENXTPA:DBV) After A 359% One-Year Surge? - Yahoo Finance hu, 12 Feb 2026 16
- DBV Technologies (NASDAQ:DBVT) Shares Gap Down - Time to Sell? - MarketBeat Wed, 11 Feb 2026 18
- Peanut allergy patch data in young children to get spotlight at AAAAI 2026 - Stock Titan ue, 10 Feb 2026 21
- DBV Technologies stock soars after positive Phase 3 trial results - Investing.com ue, 16 Dec 2025 08
- DBV's peanut allergy patch finally finds clinical success, sending shares soaring - FirstWord Pharma ue, 16 Dec 2025 08
- Did This Biotech Just Solve Peanut Allergies? Shares Catapult. - Investor's Business Daily Wed, 17 Dec 2025 08
- DBV Technologies: Uncertainty Still Exists Despite Recent 90% Rally (NASDAQ:DBVT) - Seeking Alpha hu, 11 Dec 2025 08
- Is DBV Technologies (ENXTPA:DBV) Pricing In Too Much Optimism After Its 1‑Year Surge - simplywall.st ue, 10 Feb 2026 04
- DBV Technologies (NASDAQ:DBVT) Stock Price Passes Above 50 Day Moving Average - What's Next? - MarketBeat Sat, 31 Jan 2026 08
- DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit - Yahoo Finance Mon, 09 Feb 2026 08
- DBV Technologies stock price target raised to $40 from $35 at H.C. Wainwright - Investing.com hu, 18 Dec 2025 08
- DBV Technologies (NASDAQ:DBVT) Shares Gap Up - Still a Buy? - MarketBeat Wed, 04 Feb 2026 08
- DBV Technologies (ENXTPA:DBV): Assessing Valuation After VITESSE Trial Call Puts Spotlight on Viaskin Peanut - Yahoo Finance hu, 18 Dec 2025 08
- DBV Technologies stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com hu, 15 Jan 2026 08
- DBV Technologies (NASDAQ:DBVT) Upgraded at Wall Street Zen - MarketBeat Sun, 08 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for DBV
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|